Crenolanib (CP-868596) , 98% , 670220-88-9
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB607.20 | In Stock |
|
| 10MG | RMB1151.20 | In Stock |
|
| 25mg | RMB1951.20 | In Stock |
|
| 50MG | RMB3511.20 | In Stock |
|
| 100mg | RMB6319.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 676.6±65.0 °C(Predicted) |
| Density | 1.36 |
| storage temp. | -20° |
| solubility | Soluble in DMSO (up to 15 mg/ml) or in Ethanol (up to 10 mg/ml). |
| form | solid |
| pka | 9.84±0.20(Predicted) |
| color | White |
| Stability: | Stable for 1 year as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| CAS DataBase Reference | 670220-88-9 |
Description and Uses
Crenolanib (670220-88-9) is a potent inhibitor of PDGFR (Kd?for α = 2.1 nM; β = 3.2 nM) and FLT3 (Kd?= 0.74 nM).1?Crenolanib is a type I inhibitor binding only to the active kinase conformation. It showed potent activity against imatinib-resistant PDGFRα mutations D842I, D842V, D842Y, DI842-843M, and deletion I8432?as well as FLT3/ITD and FLT3/D835 mutants3. Crenolanib acted synergistically with FLT3-CAR T-cells in a FLT3-ITD+?AML murine xenograft model.4
Crenolanib is an orally bioavailable, selective inhibitor of type III tyrosine kinases with nanomolar potencies against platelet-derived growth factor receptor α (PDGFRα) and PDGFRβ and Fms-related tyrosine kinase 3 (FLT3; IC50s = 11, 3.2, and 4 nM, respectively). It also inhibits medically-relevant mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations. Crenolanib is more than 100-fold selective for these kinases over other tyrosine and serine/threonine kinases. It is effective when used in cells and in vivo.[Cayman Chemical]
